The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
Open accessAbstract
BACKGROUND: There are limited data on the effectiveness of the vaccines against symptomatic coronavirus disease 2019 (Covid-19) currently authorized in the United States with respect to hospitalization, admission to an intensive care unit (ICU), or ambulatory care in an emergency department or urgent care clinic. METHODS: We conducted a study involving adults (≥50 years of age) with Covid-19-like illness who underwent molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed 41,552 admissions to 187 hospitals and 21,522 visits to 221 emergency departments or urgent care clinics during the period from January 1 through June 22, 2021, in multiple states. The patients' vaccination status was documented in electronic health records and immunization registries. We used a test-negative design to estimate vaccine effectiveness by comparing the odds of a positive test for SARS-CoV-2 infection among vaccinated patients with those among unvaccinated patients. Vaccine effectiveness was adjusted with weights based on propensity-for-vaccination scores and according to age, geographic region, calendar time (days from January 1, 2021, to the index date for each medical visit), and local virus circulation. RESULTS: The effectiveness of full messenger RNA (mRNA) vaccination (≥14 days after the second dose) was 89% (95% confidence interval [CI], 87 to 91) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization, 90% (95% CI, 86 to 93) against infection leading to an ICU admission, and 91% (95% CI, 89 to 93) against infection leading to an emergency department or urgent care clinic visit. The effectiveness of full vaccination with respect to a Covid-19-associated hospitalization or emergency department or urgent care clinic visit was similar with the BNT162b2 and mRNA-1273 vaccines and ranged from 81% to 95% among adults 85 years of age or older, persons with chronic medical conditions, and Black or Hispanic adults. The effectiveness of the Ad26.COV2.S vaccine was 68% (95% CI, 50 to 79) against laboratory-confirmed SARS-CoV-2 infection leading to hospitalization and 73% (95% CI, 59 to 82) against infection leading to an emergency department or urgent care clinic visit. CONCLUSIONS: Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection. (Funded by the Centers for Disease Control and Prevention.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Self-citationHospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660
George, S., Duran, N., & Norris, K. (2014) · American Journal of Public Health · doi:10.2105/ajph.2013.301706 · Cited by 1,603
Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
McCaffrey, D. F., Ridgeway, G., & Morral, A. R. (2004) · Psychological Methods · doi:10.1037/1082-989x.9.4.403 · Cited by 1,317
Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 939
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
(2021) · New England Journal of Medicine · doi:10.1056/nejmc2036242 · Cited by 831
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707
Self-citationKim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., Armistead, I., Bennett, N. M., Billing, L., Como-Sabetti, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1012 · Cited by 649
Self-citationAzar, K. M. J., Shen, Z., Romanelli, R. J., Lockhart, S. H., Smits, K., Robinson, S., Brown, S., & Pressman, A. R. (2020) · Health Affairs · doi:10.1377/hlthaff.2020.00598 · Cited by 559
Nguyen, T.-L., Collins, G. S., Spence, J., Daurès, J.-P., Devereaux, P. J., Landais, P., & Le Manach, Y. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0338-0 · Cited by 512
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A. L., Lutrick, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107058 · Cited by 485
Self-citationKillerby, M. E., Link-Gelles, R., Haight, S. C., Schrodt, C. A., England, L., Gomes, D. J., Shamout, M., Pettrone, K., O'Laughlin, K., Kimball, A., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6925e1 · Cited by 357
Self-citationChung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., et al. (2021) · BMJ · doi:10.1136/bmj.n1943 · Cited by 307
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., & Leshem, E. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00448-7 · Cited by 306
Tenforde, M. W., Olson, S. M., Self, W. H., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e1 · Cited by 294
Self-citationGu, T., Mack, J. A., Salvatore, M., Prabhu Sankar, S., Valley, T. S., Singh, K., Nallamothu, B. K., Kheterpal, S., Lisabeth, L., Fritsche, L. G., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25197 · Cited by 260
De Serres, G., Skowronski, D. M., Wu, X. W., & Ambrose, C. S. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.37.20585 · Cited by 245
Thompson, M. G., Kwong, J. C., Regan, A. K., Katz, M. A., Drews, S. J., Azziz-Baumgartner, E., Klein, N. P., Chung, H., Effler, P. V., Feldman, B. S., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy737 · Cited by 184
Self-citationChua, H., Feng, S., Lewnard, J. A., Sullivan, S. G., Blyth, C. C., Lipsitch, M., & Cowling, B. J. (2020) · Epidemiology · doi:10.1097/ede.0000000000001116 · Cited by 164
On the Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies
Mansson, R., Joffe, M. M., Sun, W., & Hennessy, S. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm069 · Cited by 155
Cates, J., Lucero-Obusan, C. A., Dahl, R. M., Schirmer, P., Garg, S., Oda, G., Hall, A. J., Langley, G., Havers, F. P., Holodniy, M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6942e3 · Cited by 147
Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada
Wingert, A., Pillay, J., Gates, M., Guitard, S., Rahman, S., Beck, A., Vandermeer, B., & Hartling, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044684 · Cited by 89
Recruitment and Retention of Elderly Patients in Clinical Trials: Issues and Strategies
Cassidy, E. L., Baird, E., & Sheikh, J. I. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200105000-00005 · Cited by 82
Ferdinands, J. M., Gaglani, M., Martin, E. T., Middleton, D., Monto, A. S., Murthy, K., Silveira, F. P., Talbot, H. K., Zimmerman, R. K., Alyanak, E., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy723 · Cited by 79
Self-citationFoppa, I., Ferdinands, J. M., Chaves, S. S., Haber, M., Reynolds, S. B., Flannery, B. L., & Fry, A. M. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw022 · Cited by 66
Self-citationAge and frailty in COVID-19 vaccine development
Andrew, M. K., & McElhaney, J. E. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32481-8 · Cited by 65
Kwong, J. C., Campitelli, M. A., Gubbay, J. B., Peci, A., Winter, A.-L., Olsha, R., Turner, R., Rosella, L. C., & Crowcroft, N. S. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit404 · Cited by 61
Ferdinands, J. M., & Shay, D. K. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir750 · Cited by 35
Self-citationConsidering Frailty in SARS-CoV-2 Vaccine Development: How Geriatricians Can Assist
Andrew, M. K., Schmader, K. E., Rockwood, K. J., Clarke, B., & McElhaney, J. E. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295522 · Cited by 29
Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S., Chen, B., Calzavara, A. J., Fell, D. B., Austin, P. C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3845993 · Cited by 26
Ferdinands, J. M., Belongia, E. A., Nwasike, C., & Shay, D. K. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.098 · Cited by 15
Self-citation
Cited by
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7107e2 · Cited by 435
Self-citationThompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7104e3 · Cited by 398
“529 (Omicron) 18,027 (8) 6,996 (39) 1,746 (10) 5,409 (30) 3,876 (22) 6,546 (36)”
MethodResultSelf-citationBruxvoort, K. J., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Lee, G. S., Tian, Y., Florea, A., Aragones, M., Tubert, J. E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-068848 · Cited by 230
Metadata
- Authors
- Thompson, M. G., Stenehjem, E., Grannis, S., Ball, S. W., Naleway, A. L., Ong, T. C., DeSilva, M. B., Natarajan, K., Bozio, C. H., Lewis, N., Dascomb, K., Dixon, B. E., Birch, R. J., Irving, S. A., Rao, S., Kharbanda, E., Han, J., Reynolds, S., Goddard, K., Grisel, N., Fadel, W. F., Levy, M. E., Ferdinands, J., Fireman, B., Arndorfer, J., Valvi, N. R., Rowley, E. A., Patel, P., Zerbo, O., Griggs, E. P., Porter, R. M., Demarco, M., Blanton, L., Steffens, A., Zhuang, Y., Olson, N., Barron, M., Shifflett, P., Schrag, S. J., Verani, J. R., Fry, A., Gaglani, M., Azziz-Baumgartner, E., & Klein, N. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-07
- Volume
- 385
- Issue
- 15
- Pages
- 1355-1371
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3198593250
- Cited by
- 468
- References
- 40
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.